Applied Biocatalysis and Enzyme Engineering on September 30-October 01, 2026 in Boston, United States

Advances in AI, machine learning, and predictive enzyme engineering are making biocatalysis faster, more efficient, and increasingly scalable. At the same time, growing adoption across peptides, oligonucleotides, ADCs, and other high-value modalities - combined with rising investment in enzyme platforms and specialist providers - is accelerating innovation across the field.

However, as new technologies, applications, and outsourcing models continue to emerge, organisations face a key challenge: identifying which approaches deliver real-world impact and successfully translating innovation into scalable, commercially viable processes.

The 6th Applied Biocatalysis and Enzyme Engineering Summit returns as the only industry dedicated forum dedicated to helping scientists and biocatalysis leaders navigate this rapidly evolving landscape. Through two days of case studies, technical discussions, and collaborative networking, attendees will gain the practical insights needed to accelerate development, improve process efficiency, and unlock greater value from enzyme engineering.

The summit currently stands as the only industry meeting that:

- Focuses specifically on the practical application of biocatalysis and enzyme engineering to showcase real-world implementation, scale-up, and commercial success stories

- Brings together leaders from pharma, biotech, academia, and enzyme service providers in one forum, creating a unique opportunity to benchmark strategies, exchange learnings, and identify new collaboration opportunities across the biocatalysis ecosystem

- Explores the technologies and trends shaping the future of the field, from AI-driven enzyme design and data strategies to emerging modalities, industrial deployment, and next-generation bioprocessing approaches

Join your peers to separate AI hype from reality, uncover strategies that are delivering measurable impact today, and build the partnerships that will help accelerate the next generation of biocatalysis innovation.

URLs:
Tickets: https://go.evvnt.com/3678785-2?pid=10008
Brochure: https://go.evvnt.com/3678785-3?pid=10008

Time: 8:00 AM - 4:00 PM

Venue Details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United States

Category: Conferences | Science, Health and Medicine

Prices:
Drug Developer Pricing - Conference Only: USD 0.00,
Service and Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Ryan Phelan, Principal Scientist, Biocatalysis Lead, Abbvie, Doug Millar, Senior Scientist, Process Development, Amgen, Eric Olmon, Principal Scientist, CMC Development, Alnylam Pharmaceuticals, Catalina Parga, Senior Scientist, Process Development, Alnylam Pharmaceuticals, Xu Ma, Senior Scientist, Process Research, Boehringer Ingelheim, Adrian Ortiz, Executive Director, Process Research and Development, Eli Lilly, Deeptak Verma, Director of Computational Chemistry (Modeling and Informatics), Merck and Co, Emily Greenhagen, Director, Microbial Process Operations, Merck and Co, Chris Schneider, Senior Scientist II, Novo Nordisk, Jovan Livada, Senior Scientist, Pfizer, Jason Tedrow, Head of Process Chemistry, Sanofi, Kui Chan, Principal Scientist, Cyrus Biotechnology, Giota Kyriakou, Associate Director, Protein and RNA Engineering, Tessera Therapeutics, Kathleen Sicinski, Staff Scientist, Protein Engineer, Arnold Lab, Caltech, Carlos Acevedo-Rocha, Senior Research (Associate Professor), DTU BRIGHT The Novo Nordisk Foundation Biotechnology Research Institute, Yannick Bomble, Distinguished Principal Scientist, NREL, Todd Hyster, Professor of Chemistry, Princeton University, Rudi Fasan, Chair of Chemistry, University of Texas, Dallas, Lola Le Breton, PhD Candidate, Mila Quebec AI Institute